Biological age—how fast someone's body is actually aging—often diverges from chronological age. Some 60-year-olds have the health profile of a 45-year-old, while others resemble 75-year-olds. Current aging clocks rely on DNA methylation patterns (epigenetic clocks) or blood biomarkers, but metabolism is a largely unexplored dimension. This study asks: can we measure all small molecules circulating in blood and use them to build a better aging clock?
The researchers analyzed metabolites (products of cellular metabolism) from 2,295 participants aged 20–89 in two cohorts: the UK Airwave study (960 people) and the Irish Longitudinal Study on Ageing (1,335 people). Using liquid chromatography–mass spectrometry (LC-MS), they measured hundreds of metabolites per person. They identified four metabolites most strongly linked to aging: N2,N2-dimethylguanosine, C-glycosyltryptophan, bile acid glucuronides, and zeta-carotene. Using machine learning, they built a metabolomic clock that predicted chronological age with very high accuracy (r = 0.92).
They then calculated 'metabolomic age acceleration'—the difference between predicted metabolomic age and actual age. In fully adjusted statistical models, each 5-year increase in metabolomic age acceleration was associated with: 43% higher mortality risk, 27% higher risk of mild cognitive impairment, and 10% increased frailty risk. The acceleration metric was reproducible across study visits (r > 0.6), suggesting it's a stable marker of an individual's aging trajectory.
Importantly, this is a preprint—not yet peer-reviewed—so findings require independent replication before clinical use. The study is cross-sectional and observational; while associations are strong, causality cannot be inferred. The mechanism by which these four metabolites specifically drive aging remains unexplained. The metabolites identified are biologically plausible (guanosine derivatives relate to nucleotide metabolism, bile acids to gut-liver health, carotenes to antioxidant status), but the 'why' needs investigation. Missing is information on data availability, whether the analysis was preregistered, and potential conflicts of interest.
This work contributes to the aging biomarker toolkit by adding a metabolomic dimension complementary to epigenetic and proteomic clocks. If replicated in independent cohorts and validated prospectively, a metabolomic clock could help identify people aging faster than expected and potentially guide intervention. However, the predictive value for individual-level decision-making remains unclear, and it is unknown whether interventions that 'reset' metabolomic age actually extend life or improve health. The paper represents a solid discovery study but should be interpreted as hypothesis-generating rather than clinically actionable until peer review and replication.
0 Comments
Log in to join the discussion.